• Clearside Biomedical

    Clearside Biomedical

    • Clinical-stage ophthalmic pharmaceutical company with pivotal trial planned for initiation in late 2013
    • Scientific founders: Dr. Mark Prasunitz at Georgia Tech and Dr. Henry Edelhauser at Emory
    • Clearside’s proprietary, disruptive microinjection platform delivers drug through the suprachoroidal space (“SCS”), providing drug to the diseased area of the retina to treat sight-threatening diseases
    • Procedure has been tested for safety/tolerability in the clinic as the only office-based, non-surgical drug delivery to the SCS
    • Funded in January 2012, management efficiently used capital to advance from preclinical development to first clinical trial in less than 1 year
    • Hatteras holds 2 board seats including Board Chair
  • G1 Therapeutics, Inc.

    G1 Therapeutics, Inc.

    • Innovative, scientifically-robust platform of novel, potent and selective CDK4/6 inhibitors to protect bone marrow from chemotherapy and ionizing radiation
    • Scientific founders: Dr. Ned Sharpless at UNC and Dr. Kwok Kim-Wong at Dana-Farber/Harvard
    • Awarded over $4M in NIH funding to date in addition to funding through the North Carolina Biotechnology Center
    • Funded in August 2012, investment will accelerate pre-clinical timeline by 1 year, providing financing toward lead molecule selection and pre-IND enabling work
    • Hatteras holds 2 board seats
  • Coferon


    • Creating molecules with highly tunable structures to increase drug-like properties to treat unmet and undermet medical needs
    • Scientific founders: Dr. Francis Barany and Dr. Maneesh Pingle at Weill-Cornell Medical College and Dr. Don Bergstrom at Purdue University
    • CEO is Colin Goddard, PhD, former CEO of OSI Pharma and member of the Hatteras Discovery Portfolio Review Committee
    • Funded in June 2012
    • Hatteras holds one board seat